Toward an HIV vaccine: A scientific journey

Science

Volumn 349, Issue 6246, 2015, Pages 386-387

  Fauci, Anthony S ^a   Marston, Hilary D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; EPITOPE; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; GP160 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; NEUTRALIZING ANTIBODY;

DISEASE TREATMENT; DRUG DEVELOPMENT; EMPIRICAL ANALYSIS; HEALTH CARE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNITY; INFECTIOUS DISEASE; VACCINE;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; CD8+ T LYMPHOCYTE; CHEMISTRY; DRUG DESIGN; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CD8-POSITIVE T-LYMPHOCYTES; DRUG DESIGN; EPITOPES; HIV ENVELOPE PROTEIN GP160; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84938228316     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aac6300     Document Type: Article

References (26)

1. W. Dowdle, Public Health Rep. 101, 232 (1986).
2. B. Korber et al., Br. Med. Bull. 58, 19 (2001).
3. R. Dolin et al., NIAID AIDS Vaccine Clinical Trials Network, Ann. Intern. Med. 114, 119 (1991).
4. A. M. Prince et al., Proc. Natl. Acad. Sci. U.S.A. 85, 6944 (1988).
5. G. Kolata, in New York Times, 16 February 1988.
6. H. Collins, in The Philadelphia Inquirer, 8 November 1994, p. A1.
7. P. Pitisuttithum et al., Bangkok Vaccine Evaluation Group, J. Infect. Dis. 194, 1661 (2006).
8. N. M. Flynn et al., rgp120 HIV Vaccine Study Group, J. Infect. Dis. 191, 654 (2005).
9. National Institutes of Health, Statement: Immunizations are discontinued in two HIV vaccine trials [press release] (2007); http://bit.ly/vaccines-discontinued.
10. A. S. Fauci., Science 344, 49 (2014).
11. S. Rerks-Ngarm et al., MOPH-TAVEG Investigators, N. Engl. J. Med. 361, 2209 (2009).
12. U.S. Military Health Research Program, Pox-Protein Public-Private Partnership (2013); www.hivresearch.org/news.php?NewsID=270&GlobalID=11.
13. B. F. Haynes et al., N. Engl. J. Med. 366, 1275 (2012).
14. B. F. Haynes, G. Kelsoe, S. C. Harrison, T. B. Kepler, Nat. Biotechnol. 30, 423 (2012).
15. M. Shingai et al., J. Exp. Med. 211, 2061 (2014).
16. D. H. Barouch et al., Nature 503, 224 (2013).
17. M. Shingai et al., Nature 503, 277 (2013).
18. T. W. Chun et al., Proc. Natl. Acad. Sci. U.S.A. 111, 13151 (2014).
19. M. Caskey et al., Nature 522, 487 (2015).
20. M. Pancera et al., Nature 514, 455 (2014).
21. J. P. Julien et al., Science 342, 1477 (2013).
22. D. Lyumkis et al., Science 342, 1484 (2013).
23. R. W. Sanders et al., PLOS Pathog. 9, e1003618 (2013).
24. R. W. Sanders et al., Science 349, 154 (2015).
25. P. Dosenovic et al., Cell 161, 1505 (2015).
26. S. G. Hansen et al., Nature 502, 100 (2013